Stone Run Capital’s Haemonetics HAE Stock Holding History

Stone Run Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-24,040	Closed	-$994K	–	69
2015 Q2	$994K	Hold	24,040	–	–	0.65%	49
2015 Q1	$1.08M	Sell	24,040 -15,700	-40%	-$656K	0.7%	50
2014 Q4	$1.39M	Hold	39,740	–	–	0.95%	44
2014 Q3	$1.39M	Sell	39,740 -12,000	-23%	-$428K	0.98%	43
2014 Q2	$1.82M	Buy	51,740 +18,000	+53%	+$601K	1.2%	39
2014 Q1	$1.1M	Buy	+33,740	New	+$1.29M	0.8%	47

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Stone Run Capital's HAE Position: Q3 2015 in Review

Stone Run Capital sold out of Haemonetics (HAE) in Q3 2015, closing a stake of 24,040 shares — an estimated $994K sold.

Stone Run Capital first reported a position in HAE in Q1 2014 and held it in 6 quarters. The position peaked at $1.82M in Q2 2014. 172 funds tracked by Wall St. Rank hold HAE as of Q3 2015.

Stone Run Capital reported no remaining Haemonetics position as of Q3 2015 after selling out during the quarter.
Stone Run Capital sold 24,040 Haemonetics shares in Q3 2015, an estimated $994K.
Stone Run Capital first reported a position in Haemonetics in Q1 2014 and held it in 6 quarters.
Stone Run Capital's Haemonetics position peaked at $1.82M in Q2 2014.
172 funds tracked by Wall St. Rank held Haemonetics as of Q3 2015.

Based on Stone Run Capital's 13F filing for Q3 2015, filed 13 Nov 2015.